TipRanks
Advertisement
Advertisement
Hemab Therapeutics Advances HMB-003 Into Phase 1 Trial for Heavy Menstrual Bleeding
PremiumPrivate CompaniesHemab Therapeutics Advances HMB-003 Into Phase 1 Trial for Heavy Menstrual Bleeding
17d ago
Hemab Therapeutics Advances Von Willebrand Disease Program With New Clinical Studies
Premium
Private Companies
Hemab Therapeutics Advances Von Willebrand Disease Program With New Clinical Studies
26d ago
Hemab Therapeutics Highlights Patient-Centric Approach in Bleeding Disorders Care
Premium
Private Companies
Hemab Therapeutics Highlights Patient-Centric Approach in Bleeding Disorders Care
1M ago
Patient Advocacy Focus Highlights Strategic Positioning in Bleeding Disorders
PremiumPrivate CompaniesPatient Advocacy Focus Highlights Strategic Positioning in Bleeding Disorders
2M ago
Hemab Therapeutics Advances VELORA Clinical Programs in Von Willebrand Disease
Premium
Private Companies
Hemab Therapeutics Advances VELORA Clinical Programs in Von Willebrand Disease
2M ago
Hemab Therapeutics Highlights Patient Burden and Advancing GT Prophylactic Candidate
Premium
Private Companies
Hemab Therapeutics Highlights Patient Burden and Advancing GT Prophylactic Candidate
2M ago
Hemab Therapeutics Highlights Strategy in Glanzmann Thrombasthenia Market
PremiumPrivate CompaniesHemab Therapeutics Highlights Strategy in Glanzmann Thrombasthenia Market
2M ago
Hemab Therapeutics Highlights Advancing Sutacimig Program in Rare Bleeding Disorders
Premium
Private Companies
Hemab Therapeutics Highlights Advancing Sutacimig Program in Rare Bleeding Disorders
3M ago
Hemab Therapeutics Highlights Early-Stage Progress in von Willebrand Disease Pipeline
Premium
Private Companies
Hemab Therapeutics Highlights Early-Stage Progress in von Willebrand Disease Pipeline
3M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―